InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU

Reuters

Nov 10

InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU

InflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582765498"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582765498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582765498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582765498","market":"us","top_or_hot":-1,"title":"InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IFRX\">InflaRx N.V.</a> has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IFRX\">InflaRx N.V.</a> has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbGbyMg:1","article_id":"2582765498","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582765498","pubTimestamp":1762778223,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa  and chronic spontaneous urticaria . The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score  and improvements in the Urticaria Control Test . InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IFRX":"InflaRx N.V."},"translate_title":"InflaRx报告INF904在HS和CSU中的阳性2a期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":0.9},"content_text":"InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    \n\nInflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}